These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 26082780)

  • 1. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.
    Datta J; Berk E; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Front Immunol; 2015; 6():271. PubMed ID: 26082780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing dendritic cell-based approaches for cancer immunotherapy.
    Datta J; Terhune JH; Lowenfeld L; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
    Yale J Biol Med; 2014 Dec; 87(4):491-518. PubMed ID: 25506283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.
    Mac Keon S; Ruiz MS; Gazzaniga S; Wainstok R
    Front Immunol; 2015; 6():243. PubMed ID: 26042126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.
    Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ
    Front Oncol; 2019; 9():50. PubMed ID: 30788290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives on immunotherapy.
    Weber JS
    Semin Oncol; 2014 Oct; 41 Suppl 5():S14-29. PubMed ID: 25438996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
    Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
    J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.
    Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K
    Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen delivery by dendritic cells.
    Moll H
    Int J Med Microbiol; 2004 Oct; 294(5):337-44. PubMed ID: 15532992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
    Salem ML
    Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment.
    Belderbos RA; Aerts JGJV; Vroman H
    Mol Ther Oncolytics; 2019 Jun; 13():67-81. PubMed ID: 31020037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Jun; 32(6):e65-e73. PubMed ID: 29940064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
    Xu P; Wasielewski LJ; Yang JC; Cai D; Evans CP; Murphy WJ; Liu C
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell-based vaccine efficacy: aiming for hot spots.
    Pizzurro GA; Barrio MM
    Front Immunol; 2015; 6():91. PubMed ID: 25784913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in prostate cancer: current state and future perspectives.
    Handa S; Hans B; Goel S; Bashorun HO; Dovey Z; Tewari A
    Ther Adv Urol; 2020; 12():1756287220951404. PubMed ID: 32952615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.